Open AccessThe Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study
Author(s) -
Feng Zhang,
Yuyang Wang,
Fangfang Yang,
Yuming Zhang,
Man Jiang,
Xiaochun Zhang
Publication year - 2022
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s349442
Subject(s) - gemcitabine , medicine , paclitaxel , incidence (geometry) , adverse effect , pancreatic cancer , gastroenterology , chemotherapy , oncology , cancer , physics , optics
The purpose of this study was to evaluate the efficacy and safety of PD-1 inhibitor combined with nab-paclitaxel plus gemcitabine (AG) chemotherapy versus AG chemotherapy in the first-line treatment of advanced pancreatic cancer.